The U.K.’s National Institute for Health and Care Excellence (NICE) has issued a draft “no” statement on the triple combination of Sarclisa (isatuximab), Pomalyst (pomalidomide) and dexamethasone as a treatment for people with relapsed or refractory multiple myeloma. This draft decision means that, at present, NICE will not recommend to the United Kingdom’s National Health Service (NHS) that the triple combination be made available to people with myeloma in England and Wales. NICE will now undergo a period of consultation…
You must be logged in to read/download the full post.
The post UK’s NICE Issues Draft ‘No’ Decision for Sarclisa Triple Combo appeared first on BioNewsFeeds.